Ostia Sciences Inc. Completes $1.46M Seed Round to Develop Microbiome Therapeutics Platform.
The company receives additional non-dilutive funding from Natural Products Canada.
Article content
TORONTO — Ostia Sciences Inc., a microbiome therapeutics company developing next-generation probiotics, today announced the successful close of its seed financing round, raising CAD $1.46 million as of December 31, 2024.
Article content
Article content
In addition to private investment, Ostia secured over $393,000 in non-dilutive grants, including $350,000 from Natural Products Canada (NPC) through its Proof-of-Concept (POC) program.
Article content
The NPC POC funding will help advance Ostia's planned clinical trials, focusing on natural solutions for widespread conditions like gingivitis, halitosis, and treatment-related oral complications of head and neck cancer patients.
Article content
'Our progress reflects both strong investor confidence and essential support from Canadian innovation programs, enabling the commercialization of natural health solutions and helping millions of patients worldwide,' said Dr. Abdelahhad Barbour, CEO of Ostia Sciences. 'We now have the resources to optimize our manufacturing processes and move SALI-10 toward clinical validation.'
Article content
With full ownership of its IP portfolio, an expanding team of advisors, and a robust discovery pipeline, Ostia Sciences is positioning itself as a leader in microbiome-based biotherapeutics.
Article content
'We're building more than just a product, we're creating a platform for targeted, microbiome-driven drug development,' said Dr. Michael Glogauer, Chief Scientific Officer. 'This funding brings us one step closer to transforming how we treat oral and respiratory diseases.'
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
8 minutes ago
- Globe and Mail
Rogers raises service revenue guidance, records steep profit decline in second quarter
Rogers Communications Inc. (RCI-B-T) raised its guidance for service revenue this year and said it would spend at the bottom of its estimated capital expenditure range in 2025, even as subscriber growth and profit declined steeply during the telecom's second quarter. Rogers reported $4.4-billion of service revenue during the three-month period ended March. 31, up 2 per cent from last year. It raised its expectations for service revenue for the year to between 3 and 5 per cent growth, up from an initial estimate of flat to 3 per cent growth. Total revenue was $5.2-billion, meeting analyst consensus. Net income was $148-million, down 62 per cent, primarily as a result of higher restructuring, acquisition and other costs. The company said it is now expecting to spend $3.8-billion in 2025, compared to an initial estimated range of between $3.8-billion to $4-billion, provided in January. Rogers added 35,000 postpaid wireless subscribers, beating analyst consensus expectations of 31,000 and sharply down 77 per cent from last year. The company added 26,000 prepaid phone subscribers, beating consensus of 22,000, down 26 per cent from last year. During a call with analysts Wednesday morning, Rogers chief executive officer Tony Staffieri acknowledged that 'the size of the net add market is lower than last year,' and said these numbers are in part the result of slowing immigration following federal target cuts and fewer student visas. Historically, Rogers has won the greatest share of new Canadian subscribers, making it particularly vulnerable to the slowing population growth. Bank of Nova Scotia analyst Maher Yaghi called the results 'broadly in line with expectations,' and said the customer loading numbers were 'relatively healthy' given continued pressure on the Canadian telecom industry and slower population growth. 'While financial results do clearly show the impact from significant pricing pressures we believe recent price ups which we saw since early June provide a more positive backdrop for the industry,' he said. Rogers closed its $6.7-billion structured equity deal with Blackstone Inc. for a portion of its backhaul network during the quarter. Previously, Rogers had said the deal was worth $7-billion. It attributed the discrepancy of $300-million to shifting exchange rates. The company had long-term debt of $39.8-billion as of July 23, down from $42.2-billion at the end of March. Following the Blackstone deal and after the end of the quarter, in July Rogers launched cash offers to repurchase up to US$1.7-billion and $1.2-billion of senior notes. Media revenue was $808-million, up 10 per cent from last year primarily as a result of higher sports-related revenue due to the success of the NHL playoffs. Last quarter, Rogers said it was in active talks with investors interested in its sports assets, as the company seeks to unlock value from its portfolio of sports holdings and boost its share price. The company closed its $4.7-billion acquisition of a portion of Maple Leaf Sports & Entertainment on July 1, one day after the end of the quarter. Rogers chief financial officer Glenn Brandt said that the company's sports assets, including the Toronto Blue Jays and the portion of Maple Leaf Sports & Entertainment recently acquired from BCE Inc., are worth about $15-billion. In July, after the end of the quarter, the company ended its contract with third-party customer service provider Foundever. Employment Law firm Samfiru Tumarkin LLP estimated this would affect approximately 900 jobs. Rogers attributed the move to a change of its 'vendor mix.' Second-quarter profit amounted to 29 cents per share, down from 74 cents per share in the same period of 2024. In recent weeks, Rogers increased its connection fee from $75 to $80, added new travel passes for 14- or 30-day periods and announced an upcoming daily roaming fee price increase of $2 per day.
Globe and Mail
8 minutes ago
- Globe and Mail
U.S. Department of Justice to Sponsor Cellebrite for FedRAMP ATO
TYSONS CORNER, Va., July 23, 2025 (GLOBE NEWSWIRE) -- Cellebrite (NASDAQ: CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced the U.S. Department of Justice (DOJ) will serve as the official sponsoring agency for the platform's pursuit of a FedRAMP High authorization. Cellebrite announced its intent to pursue FedRAMP authorization in 2024. In 2025, Cellebrite Government Cloud (CGC) was reviewed by a Third-Party Assessment Organization (3PAO), and the FedRAMP Program Management Office (PMO) prepared a Readiness Assessment Report (RAR), which granted Cellebrite Government Cloud FedRAMP High Ready status. DOJ's sponsorship is the critical step required for Cellebrite Government Cloud (CGC) to advance from its current FedRAMP High Ready designation to 'In Process' status. This marks a major milestone that significantly accelerates Cellebrite's compliance journey towards a full Authorization to Operate (ATO). 'We are proud to offer our U.S. federal customers reliable, secure and cutting-edge cloud solutions that enhance their investigative processes and expedite their missions,' said Erik Sachwitz, General Manager of Cellebrite Federal Solutions, Inc. 'We are grateful to the Justice Department for entrusting us to implement their workflow on the Cellebrite Government Cloud. This milestone marks a significant advancement to our ongoing efforts to deepen our support of U.S. federal agencies.' The Cellebrite Government Cloud (CGC) will launch with a comprehensive suite of digital investigative tools. The initial offering provides U.S. federal agencies secure access to two of the company's market-leading solutions: Cellebrite Inseyets, enabling immediate online access to Cellebrite's latest digital forensics capabilities, and Cellebrite Guardian, for collaborative digital evidence review, sharing and storage. Together, these integrated solutions are designed to deliver greater operational efficiencies, support end-to-end collaboration and strengthen the overall chain of custody to help U.S. federal agencies advance their missions while meeting the scalability and security requirements of national, regional and local public safety customers. By shifting digital investigation workflows to the cloud, agencies and attorneys gain secure, flexible access to evidence from anywhere, while also harnessing advanced analytical capabilities enabled by powerful cloud infrastructure. Demonstrating a commitment to supporting diverse missions and operational environments, Cellebrite ensures agencies will continue to have access to on-premises, hybrid and fully offline solutions, empowering them to operate effectively regardless of their unique requirements. References to Websites and Social Media Platforms References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release. About Cellebrite Cellebrite's (Nasdaq: CLBT) mission is to enable its global customers to protect and save lives by enhancing digital investigations and intelligence gathering to accelerate justice in communities around the world. Cellebrite's AI-powered Digital Investigation Platform enables customers to lawfully access, collect, analyze and share digital evidence in legally sanctioned investigations while preserving data privacy. Thousands of public safety organizations, intelligence agencies, and businesses rely on Cellebrite's digital forensic and investigative solutions—available via cloud, on-premises, and hybrid deployments—to close cases faster and safeguard communities. To learn more, visit us at and find us on social media @Cellebrite. Caution Regarding Forward Looking Statements This document includes 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the United States Private Securities Litigation Reform Act of 1995. Forward looking statements may be identified by the use of words such as 'forecast,' 'intend,' 'seek,' 'target,' 'anticipate,' 'will,' 'appear,' 'approximate,' 'foresee,' 'might,' 'possible,' 'potential,' 'believe,' 'could,' 'predict,' 'should,' 'could,' 'continue,' 'expect,' 'estimate,' 'may,' 'plan,' 'outlook,' 'future' and 'project' and other similar expressions that predict, project or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include, but are not limited to, this marks a major milestone that significantly accelerates Cellebrite's compliance journey towards a full Authorization to Operate (ATO); and we are proud to offer our U.S. federal customers reliable, secure and cutting-edge cloud solutions that enhance their investigative processes and expedite their missions are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to: Cellebrite's ability to continue advancing its FedRAMP activities to achieve full FedRAMP authorization in a timely manner; Cellebrite's ability to keep pace with technological advances and evolving industry standards; Cellebrite's material dependence on the purchase, acceptance and use of its solutions by law enforcement and government agencies; real or perceived errors, failures, defects or bugs in Cellebrite's DI solutions; Cellebrite's failure to maintain the productivity of sales and marketing personnel, including relating to hiring, integrating and retaining personnel; intense competition in all of Cellebrite's markets; the inadvertent or deliberate misuse of Cellebrite's solutions; failure to manage its growth effectively; Cellebrite's ability to introduce new solutions and add-ons; Cellebrite's dependency on its customers renewing their subscriptions and purchasing new subscriptions; the low volume of business Cellebrite conducts via e-commerce; risks associated with the use of artificial intelligence; the risk of requiring additional capital to support the growth of its business; risks associated with Cellebrite's dependency on third parties for supplying components or services and with higher costs or unavailability of materials used to create its hardware product components; fluctuations in foreign currency exchange rates; lengthy sales cycle for some of Cellebrite's solutions; near term declines in new or renewed agreements; risks associated with inability to recruit, train and retain qualified personnel and senior management; the security of Cellebrite's operations and the integrity of its software solutions against cyber-attacks, information technology system breaches or disruptions; risks associated with the negative publicity related to Cellebrite's business and use of its products; risks related to Cellebrite's intellectual property; the regulatory constraints to which Cellebrite is subject; risks associated with Cellebrite's operations in Israel, including the ongoing Israel-Hamas war, the increased tension between Israel and Iran and its proxies, including the ongoing hostilities between Israel and Hezbollah, and the risk of a greater regional conflict; risks associated with different corporate governance requirements applicable to Israeli companies and risks associated with being a foreign private issuer and an emerging growth company; market volatility in the price of Cellebrite's shares; changing tax laws and regulations; risks associated with joint, ventures, partnerships and strategic initiatives; risks associated with Cellebrite's significant international operations, including due to fluctuations in foreign currency exchange rates, rising global inflation and exposure to regions subject to political or economic instability; risks associated with Cellebrite's failure to comply with anti-corruption, trade compliance, anti-money-laundering and economic sanctions laws and regulations; risks relating to the adequacy of Cellebrite's existing systems, processes, policies, procedures, internal controls and personnel for Cellebrite's current and future operations and reporting needs; and other factors, risks and uncertainties set forth in the section titled 'Risk Factors' in Cellebrite's annual report on Form 20-F filed with the SEC on March 18, 2025, and in other documents filed by Cellebrite with the U.S. Securities and Exchange Commission ('SEC'), which are available free of charge at You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, in this communication or elsewhere. Cellebrite undertakes no obligation to update its forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. Media Victor Cooper Sr. Director of Corporate Communications + Content Operations +1 404.510.2823 Investor Relations Andrew Kramer Vice President, Investor Relations investors@ +1 973.206.7760
Globe and Mail
8 minutes ago
- Globe and Mail
Transcat to Host First Quarter Fiscal Year 2026 Conference Call and Webcast on Thursday, August 7, 2025 at 11:00 a.m. Eastern Time
Transcat, Inc. (Nasdaq: TRNS) ('Transcat' or the 'Company'), a leader in test measurement, control and calibration, announced that it will release its first quarter fiscal year 2026 results after the close of financial markets on Wednesday, August 6, 2025. The Company will host a conference call and webcast on Thursday, August 7, 2025 at 11:00 a.m. ET to review the financial and operating results for the period and discuss its corporate strategy and outlook. A question-and-answer session will follow. First Quarter Fiscal Year 2026 Conference Call Thursday, August 7, 2025 11:00 a.m. Eastern Time Dial-in – Toll-Free US / Canada: (800) 267-6316 Dial-in – Toll / International: (203) 518-9783 Conference ID: TRANSCAT (THIS CONFERENCE ID WILL BE REQUIRED FOR ENTRY) Webcast and accompanying slide presentation: A telephonic replay will be available from 3:00 p.m. ET on the day of the conference call through Thursday, August 14, 2025. To listen to the archived call, dial (844) 512-2921 from the US or Canada, or (412) 317-6671 from international locations, and enter conference ID number 11159645 or access the webcast replay at where a transcript will be posted once available. About Transcat Transcat, Inc. is a leading provider of accredited calibration, reliability, maintenance optimization, quality and compliance, validation, Computerized Maintenance Management System (CMMS), and pipette services. The Company is focused on providing best-in-class services and products to highly regulated industries, particularly the Life Science industry, which includes pharmaceutical, biotechnology, medical device, and other FDA-regulated businesses, as well as aerospace and defense, and energy and utilities. Transcat provides periodic on-site services, mobile calibration services, pickup and delivery, in-house services at its 33 Calibration Service Centers strategically located across the United States, Puerto Rico, Canada, and Ireland. Inclusive of customer embedded locations and other field offices, we operate out of more than 50 locations. The breadth and depth of measurement parameters addressed by Transcat's ISO/IEC 17025 scopes of accreditation are believed to be the best in the industry. Transcat also operates as a leading value-added distributor that markets, sells, and rents new and used national and proprietary brand instruments to customers primarily in North America. The Company believes its combined Service and Distribution segment offerings, experience, technical expertise, and integrity creates a unique and compelling value proposition for its customers. Transcat's strategy is to leverage its strong brand and unique value proposition that includes its comprehensive instrument service capabilities, enterprise asset management, and leading distribution platform to drive organic sales growth. The Company will also look to expand its addressable calibration market through acquisitions and capability investments to further realize the inherent leverage of its business model. More information about Transcat can be found at:
